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Comparison of Laparoscopic and Percutaneous
Cryoablation of Renal Tumors: A Cost Analysis
Khalid Badwan, M.D.,1 Keegan Maxwell, M.D.,1 Ramakrishna Venkatesh, M.D.,1
Robert S. Figenshau, M.D.,1 Dan Brown, M.D.,2 Cathy Chen, M.D.,1 and Sam B. Bhayani, M.D.1

Abstract

Cryoablation of renal masses is an evolving in situ ablative technique for the management of localized renal
masses and can be performed in a laparoscopic or percutaneous manner. Its usefulness is increasing and correlates with the increasing frequency of incidentally diagnosed renal lesions. At present, this technique has been
applied to patients deemed to be poor surgical candidates for extirpative therapy or those with a strong desire
to avoid surgery, at least until long-term data become available to fully evaluate its cancer-control effectiveness. In addition, as costs become an ever more critical factor in healthcare, the costs of various management
options for clinically localized kidney cancer will become as important as clinical outcomes in deciding appropriate treatment. We compare laparoscopic and percutaneous renal cryoablation from a cost perspective.
Our findings indicate that percutaneous renal cryoablation may have distinct cost advantages over its laparoscopic counterpart. It remains to be seen whether these differences will translate into an overall increase in reliance on the percutaneous approach for renal cryoablation.
Introduction

N

EPHRON-SPARING SURGERY

(NSS) is becoming the new
standard of care for the management of clinically localized renal cell carcinoma.1 To date, extirpative as well as
ablative therapies in the form of radiofrequency ablation and
cryoablation have been used, with various advantages and
disadvantages to each. Gill and associates2 have recently
shown that patients undergoing laparoscopic cryoablation
(LCA) for small renal masses have a 98% cancer-specific
overall survival at 3 years, with only two cases of persistent
cancer at postoperative biopsy. With such encouraging early
reports, cryoablation will increasingly be used for the management of renal lesions, with the decision to use the laparoscopic or percutaneous approach based largely on the location of the tumor and the patient comorbidity profile.
From a socioeconomic standpoint, these two approaches
differ significantly. Various issues have limited previous attempts at direct cost comparison. These include differences
in billing codes at different institutions, regional insurance
compensation differences, technical differences in the number of cryoprobes used by surgeons and interventional radiologists as well as other disposable equipment, and differences in the postoperative radiologic follow-up regimen
that can contribute significant costs to overall management.

1Division

We compare overall and categorical costs associated with
LCA and percutaneous cryoablation (PCA) at Washington
University Medical Center.
Materials and Methods
From January 1, 2004, to August 31, 2006, a total of 23 LCA
procedures were performed at Barnes Jewish hospital by various surgeons (SBB, RSF, and RV). In the same time interval,
a total of 13 PCA procedures were also performed by one
radiologist (DB). Charges incurred were determined to calculate total, anesthesia, operating room, hospital admission,
and surgeon charges.
Percutaneous renal cryoablation
A total of 13 procedures were performed percutaneously
by a single interventional radiologist (DB) under regional
anesthesia. Costs incurred during these procedures included
radiologist fees, radiology department fees (CT), disposables, and hospital admission costs (if applicable). Two of 13
patients were admitted to the hospital postoperatively, and
those costs were included in our figures. Generally, our indications for PCA include small renal masses (generally less
than 3 cm), advanced age, presence of comorbid conditions
precluding other procedures that require general anesthesia,
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Conversely, PCA can be performed on an outpatient basis and is associated with less postoperative pain. With the
ability to perform live CT fluoroscopy, real-time assessment
of ice ball progression to ensure total lesion ablation is now
possible. The indications for each of these procedures continue to evolve with their respective technologies and operator expertise.
From a socioeconomic standpoint, these procedures are
strikingly different. Given the current medical climate of promotion of outpatient medical care, PCA eliminates many
hospital charges, most notably admission and operating
room costs.
Previous investigators have demonstrated a cost advantage for laparoscopic renal surgery over its open counterpart, lending further support for implementing laparoscopic
renal surgery as standard of care for most renal lesions today.4 In addition, current socioeconomic pressures from
third-party payers steer our surgical algorithms for management of clinically localized renal cell lesions, as long as
cancer control is not jeopardized.
Our analysis reveals striking cost differences between
LCA and PCA. At present, it is unclear what percentage of
patients undergoing LCA or PCA experience failure and go
on to extirpative therapy. This may change the overall costs
of these procedures and will need to be analyzed in future
series.
Link and colleagues3 recently published their analysis of
the cost differences between laparoscopic and percutaneous
approaches to nephron-sparing procedures. They compared
open partial nephrectomy, laparoscopic partial nephrectomy, LCA, and PCA and found that PCA was 2.2 to 2.7
times less costly than the other options, with savings of about
$5000 per patient. Novel to their approach is the use of detailed computer models to standardize patient costs based
on historic data from their institution. Comparing our data,
PCA at Washington University costs $4776 (excluding two
patient admissions) compared with $3109 in their analysis.
Extra cryoprobes used account for the difference between the
values. Figures for LCA could not be compared, given their

and posterior tumors amenable to percutaneous access on
preoperative imaging. Patient preference is also considered
after patients are thoroughly informed of their options and
of long-term risks and benefits of each procedure.
Laparoscopic renal cryoablation
LCA is performed in a transabdominal or retroperitoneal
approach, depending on the location of the mass. Indications
include tumor size less than 4 cm, and the patient amenable
to surgical intervention. Length of postoperative admission
averages 3.3 days (median 2 d). Costs incurred for these procedures include admission, operating room, disposables,
surgeon, anesthesia, and pathology laboratory fees.
Results
LCA average total costs were calculated to be $32,900, with
a median total cost of $29,617 (Table 1). These totals include
costs for the laparoscopic procedure, admission costs, and
physician fees. The average cost billed for PCA is $9,240, with
a median total cost of $6,861. An attempt was also made by
the authors to determine the actual collection rate, given that
institutions may charge different rates for the same procedure but collection rates tend to be more standardized. Only
Medicare collection information was available to us, and the
Medicare collection rate was used for all data. Using these
figures, LCA collects $14,346 and PCA $4,134.
Discussion
LCA and PCA are different procedures with a similar end
point: Cryoablation of the renal tumor. In spite of these similarities; there are important present differences. The laparoscopic approach obviously affords live visual and ultrasonographic feedback of the progress of the ice ball, is able
to target lesions not amenable to the percutaneous approach,
enables the surgeon to obtain a core biopsy specimen, and
allows the surgeon to determine early if probe site bleeding
needs to be addressed. In addition, nearby vital structures
can be more easily avoided under vision.

TABLE 1. CATEGORICAL BREAKDOWN OF CHARGES INCURRED FOR BOTH LAPAROSCOPIC AND
PERCUTANEOUS RENAL CRYOABLATION AT WASHINGTON UNIVERSITY MEDICAL CENTERa

LCA
PCA

Adm
days

Lap
fees

Anesth fees

US fees

Path
fees

OR
charges

Radiology
fees

3.3
(2)
0.3
(0)

$3415
($3060)
N/A

$2790
($2630)
N/A

$317
($206)
N/A

$286
($280)
N/A

$12,047
($11,560)
N/A

N/A

Category
Radiology
Surgical fees
Pathology
Hospital charges
aAverage

$527
(615)

Hospital fees

Cryoprobes
used

Total avg
(median)

$26,085
($23,473)
$6838
($4759)

2.45
(3)
4.2
(4)

$32,900
($29,617)
$9240
($6861)

Percent collected

Adjusted percentageb

0.71
0.37
0.48
0.55

0.125
0.810
0.050
0.010

values are provided (median values).
on percent collected and overall percent of costs obtained from Medicare reimbursement rates.
Adm  admission days; Lap fees  laparoscopic surgical fees; Anesth fees  anesthesiology fees; US fees  ultrasound operator fee; path
fees  pathology laboratory fees; OR charges  total operating room charges. Hospital fees include radiology fees, OR charges (for LCA),
path fees, US fees, anesth fees, lap fees, in addition to admission charges, if patient was admitted.
bBased
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use of operating room time, which was not available in our
analysis.
With an annual incidence of approximately 30,000 cases
per year (and many amenable to NSS), trends in management can translate into wide cost differences.
Conclusion
LCA and PCA are being increasingly used for management of clinically localized renal lesions. Their indications
are evolving with their respective technologies and operator
expertise. We report a significant current cost advantage for
the percutaneous approach. Given that current indications
for these procedures are different (i.e., location of tumor, patient comorbidity profile), this may confer a future advantage for the percutaneous approach. In addition, it is not our
aim to promote one of these approaches; rather, we simply
report of differences in costs. One would have to consider
the effectiveness of the two techniques in tumor ablation as
multiple attempts for ablating the same tumor would change
these results dramatically. That information is not currently
available and would have to be updated in future reports.
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